Meet the Team: Eleanor Fallon, MD
Eleanor Fallon, MD, joined Roswell Park Comprehensive Cancer Center to combine her two passions: treating melanoma and non-melanoma skin cancers and research into how immunotherapy can be used to make other therapies more effective.
Clinical Scorecard: Meet the Team: Eleanor Fallon, MD
At a Glance
Category Detail
Condition Melanoma and non-melanoma skin cancers Key Mechanisms Immunotherapy, tumor immune microenvironment, immune checkpoint blockade, intralesional therapies Target Population Patients with melanoma and non-melanoma skin cancers Care Setting Comprehensive cancer center
Key Highlights
Focus on combining treatment and research in melanoma and skin cancers Investigating the tumor immune microenvironment and its modulation Research on gut microbiome's impact on immunotherapy resistance Emphasis on precision therapy and lifestyle modifications Collaboration between surgical oncology and immunology Guideline-Based Recommendations
Diagnosis
Utilize clinical trials to inform treatment decisions Assess tumor immune microenvironment for personalized therapy Management
Incorporate immunotherapy as a primary treatment for melanoma Explore regional and intralesional therapies for advanced disease Monitoring & Follow-up
Monitor patient response to immunotherapy and adjust treatment accordingly Evaluate lifestyle and dietary factors that may influence treatment outcomes Risks
Potential resistance to immunotherapy Variability in patient responses based on immune system health Patient & Prescribing Data
Patients with advanced melanoma and non-melanoma skin cancers
Combination therapies and lifestyle modifications may enhance treatment efficacy
Clinical Best Practices
Adopt a multidisciplinary approach in cancer treatment Stay updated on the latest research in immunotherapy Encourage patient participation in clinical trials References
